HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ionescu, A.A. Articles by Schoon, E. Search for Related Content PubMed PubMed Citation Articles by Ionescu, A.A. Articles by Schoon, E.

Osteoporosis in chronic obstructive pulmonary disease

¹ Section of Respiratory and Communicable Diseases, Dept of Medicine, University of Wales, College of Medicine, Llandough Hospital, Penarth, Wales, UK, ² Catharina Ziekenhuis, Afdeling Interne Geneeskunde, Eindhoven, The Netherlands

CORRESPONDENCE: A.A. Ionescu, Section of Respiratory and Communicable Diseases, Dept of Medicine, University of Wales, College of Medicine, Llandough Hospital, Penlan Road, Penarth, CF64 2XX, Wales, UK. Fax: 44 2920716416. E-mail: ionescuaa@cardiff.ac.uk

Keywords: chronic obstructive pulmonary disease, fractures, osteoporosis, osteopenia

Received: June 30, 2003
Accepted June 30, 2003

Osteoporosis is one of the systemic effects associated with chronic obstructive pulmonary disease (COPD). Potential risk factors of osteoporosis may be due to the lifestyle, genetics, treatment with corticosteroids, endocrine abnormalities or the impairment of the body composition and peripheral skeletal muscles. Evidence for the possible contribution of such factors is reviewed.

The occurrence of fractures, as a consequence of osteoporosis, can contribute to the disability and mortality of patients with COPD and add to the economic burden of the disease. The treatment with corticosteroids for the lung disease is associated with increased prevalence of fractures, but other factors may contribute.

There is a remarkable paucity of interventional studies targeting the osteoporosis in patients with COPD. The results of studies on the treatment of osteoporosis in chronic lung diseases, some including small numbers of patients with COPD, are reviewed in the paper.

Prospective longitudinal studies on the incidence of osteoporosis in chronic obstructive pulmonary disease need to assess patients with various degrees of disease severity and investigate the possible contribution of etiological factors. Randomised placebo-controlled trials are required to assess the effect of intervention, such as bisphosphonates, hormone replacement, calcium supplementation, on the prevention and treatment of osteoporosis and fractures in chronic obstructive pulmonary disease.